Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D6SJ0B
|
|||
| Drug Name |
PF-07901801
|
|||
| Synonyms |
maplirpacept
Click to Show/Hide
|
|||
| Drug Type |
Fusion protein
|
|||
| Indication | Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3; ICD-9: 200] | Phase 2 | [1] | |
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 1/2 | [2] | ||
| Company |
Pfzer
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | CD47-SHPS1 interaction (CD47-SHPS1 PPI) | Target Info | Inhibitor | [1] |
| Leukocyte surface antigen CD47 (CD47) | Target Info | Inhibitor | [1] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05626322) A PHASE 1b/2 STUDY OF PF-07901801, A CD47 BLOCKING AGENT, WITH TAFASITAMAB AND LENALIDOMIDE FOR PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT05261490) A Phase 1/2 Study of TTI-622 in Combination With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.